Altimmune Analyst Ratings
Buy Rating on Altimmune: Pemvidutide's Market Potential in Obesity and Beyond
Evercore ISI Remains a Buy on Altimmune (ALT)
Buy Rating Affirmed for Altimmune as Pemvidutide Poised to Lead NASH Treatment Market
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Announces Target Price $20
Altimmune Analyst Ratings
Buy Rating Affirmed for Altimmune on Promising Pemvidutide Data and Market Position
Buy Rating Justified by Altimmune's Promising Pemvidutide Efficacy in NASH Treatment
Altimmune Analyst Ratings
Buy Rating Justified: Altimmune's Pemvidutide Shows Best-in-Class Potential for Obesity and MASH
Buy Rating Affirmed for Altimmune on Pemvidutide's Potential and Strategic Advancements
Altimmune Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Evolent Health (EVH) and Cormedix (CRMD)
Altimmune Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Altimmune Analyst Ratings
Altimmune's Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating
Altimmune Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)